Anzeige
Mehr »
Login
Montag, 20.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AF74 | ISIN: US44842L1035 | Ticker-Symbol: H7T1
Siehe auch HUTCHMED CHINA LIMITED
Tradegate
17.05.24
16:04 Uhr
18,800 Euro
+0,200
+1,08 %
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
HUTCHMED CHINA LIMITED ADR Chart 1 Jahr
5-Tage-Chart
HUTCHMED CHINA LIMITED ADR 5-Tage-Chart
RealtimeGeldBriefZeit
18,10019,00019.05.
18,40018,70017.05.

Aktuelle News zur HUTCHMED CHINA LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrIN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan Eldar1
FrHUTCHMED (China) Limited: HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees127HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:?HCM, HKEX:?13) today announces:- (a) the retirement...
► Artikel lesen
FrHUTCHMED Ltd - 6-K, Report of foreign issuer1
FrHutchmed China Ltd - Retirement of Chairman and new Chairman appointed1
FrHUTCHMED (00013): HUTCHMED ANNOUNCES RETIREMENT OF CHAIRMAN, APPOINTMENT OF NEW CHAIRMAN AND CHANGE OF MEMBERS OF BOARD COMMITTEES1
FrHutchmed China Ltd - HUTCHMED Data to be Presented at EHA2024 Congress-
FrHUTCHMED (China) Limited: HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress33HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from...
► Artikel lesen
FrHUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED HIGHLIGHTS SOVLEPLENIB PHASE III ESLIM-01 STUDY AND HEMATOLOGICAL MALIGNANCY PROGRAMS DATA TO BE PRESENTED ...1
DoRisk adjusted net present value: What is the current valuation of Hutchmed China's Amdizalisib?1
DiHutchmed announces trials of HMPL-306 and Surufatinib cancer therapies1
DiHutchmed China launches two cancer treatment trials1
DiHutchmed China Ltd - HUTCHMED Initiates Phase II/III Trial with Hengrui-
DiHutchmed China Ltd - HUTCHMED Initiates Registrational Phase III Trial-
DiHUTCHMED (China) Limited: HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui54- Almost half a million people diagnosed each year across the globe - - Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufatinib...
► Artikel lesen
DiHUTCHMED (China) Limited: HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China50HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational...
► Artikel lesen
DiHUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED INITIATES THE RAPHAEL REGISTRATIONAL PHASE III TRIAL OF HMPL-306 FOR PATIENTS WITH IDH1- AND/OR IDH2-MUTATED ...1
DiHUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED INITIATES PHASE II/III TRIAL OF THE COMBINATION OF SURUFATINIB AND CAMRELIZUMAB FOR TREATMENT-NAIVE ...1
13.05.HUTCHMED (00013): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
10.05.HUTCHMED (00013): ANNUAL GENERAL MEETING HELD ON MAY 10, 2024 - POLL RESULTS2
10.05.Hutchmed China Ltd - Result of AGM1
Seite:  Weiter >>
155 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1